Cingulate Inc (CING)

07:41 AM

What drives Cingulate Inc. Equity Warrant stock priceSuperior returns - Jammu Links News

07:41 AM

06:57 AM

Cingulate Inc. Stock Analysis and ForecastFree Market Volatility Navigation Tips - Jammu Links News

06:57 AM

03:02 AM

What makes Cingulate Inc. Equity Warrant stock attractive to long term investorsSmart Trading With Safety Margin - Newser

03:02 AM

02:36 AM

Cingulate Inc. Equity Warrant Stock Analysis and ForecastTremendous growth opportunities - Jammu Links News

02:36 AM

Jul 17, 2025

Why Cingulate Inc. stock attracts strong analyst attentionLow Risk ROI Maximization - Newser

Jul 17, 2025

Jul 15, 2025

How Cingulate Inc. stock performs during market volatilityFree Market Analysis Group - Newser

Jul 15, 2025

Jul 15, 2025

Why Cingulate Inc. Equity Warrant stock attracts strong analyst attentionQuick Profit Idea Stream - Newser

Jul 15, 2025

Jul 15, 2025

What makes Cingulate Inc. Equity Warrant stock price move sharplyShort Term Risk Controlled Alerts - Newser

Jul 15, 2025

Jul 15, 2025

How Cingulate Inc. Equity Warrant stock performs during market volatilityFree Stock Index Interpretation - Newser

Jul 15, 2025

Jul 15, 2025

What makes Cingulate Inc. stock price move sharplyFree Stock Movement Tracking - Newser

Jul 15, 2025

Jul 10, 2025

Cingulate hires chief legal officer ahead of filing for FDA approval - The Business Journals

Jul 10, 2025

Jul 10, 2025

Cingulate appoints Nilay Patel as Chief Legal Officer - TipRanks

Jul 10, 2025

Jul 10, 2025

Cingulate names Nilay Patel as chief legal officer ahead of FDA filing By Investing.com - Investing.com South Africa

Jul 10, 2025

Jul 09, 2025

Cingulate Inc. Appoints Nilay Patel as Chief Legal Officer - MarketScreener

Jul 09, 2025

Jul 09, 2025

Cingulate names Nilay Patel as chief legal officer ahead of FDA filing - Investing.com

Jul 09, 2025

Jul 09, 2025

Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application - GlobeNewswire

Jul 09, 2025

Jul 09, 2025

Cingulate Bolsters Executive Team With Key Legal Hire as ADHD Drug Heads to FDA Review - Stock Titan

Jul 09, 2025

Jul 08, 2025

Cingulate (NASDAQ:CING) Stock Price Up 3.3% – Here’s What Happened - Defense World

Jul 08, 2025

Jun 18, 2025

Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING) - TradingView

Jun 18, 2025

Jun 18, 2025

Breakthrough Once-Daily ADHD Drug Targets $22B Market: Analyst Coverage Reveals Commercial Launch Plans - Stock Titan

Jun 18, 2025

Jun 14, 2025

Cingulate Inc. (NASDAQ:CING) Sees Large Increase in Short Interest - Defense World

Jun 14, 2025

Jun 13, 2025

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets - mx.advfn.com

Jun 13, 2025

Jun 13, 2025

FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301 - mx.advfn.com

Jun 13, 2025

Jun 11, 2025

Cingulate Inc. expands equity plan following stockholder approval - Investing.com

Jun 11, 2025

Jun 11, 2025

Cingulate Inc Approves Key Proposals at Annual Meeting - TipRanks

Jun 11, 2025

Jun 11, 2025

Cingulate Inc. expands equity plan following stockholder approval By Investing.com - Investing.com India

Jun 11, 2025

May 28, 2025

Cingulate (NASDAQ:CING) Price Target Raised to $61.00 at Ascendiant Capital Markets - Defense World

May 28, 2025

May 27, 2025

Life365 Appoints Healthcare Veteran Jay Roberts as Chief Development Officer - Quantisnow

May 27, 2025

May 27, 2025

CING: Ascendiant Capital Raises Price Target to $61.00 | CING St - GuruFocus

May 27, 2025

May 27, 2025

Healthcare Tech Leader Life365 Taps Former Nasdaq CEO Jay Roberts to Drive AI-Powered Growth Strategy - Stock Titan

May 27, 2025

May 22, 2025

What is Roth Capital’s Estimate for Cingulate Q2 Earnings? - Defense World

May 22, 2025

May 21, 2025

McCann Joburg acquires a healthcare marketing company - Bizcommunity

May 21, 2025

May 20, 2025

Cingulate Reports Positive Data From Phase 3 Study Of CTx-1301 In Pediatric ADHD - Nasdaq

May 20, 2025

May 20, 2025

Cingulate announces efficacy results from Phase 3 study of CTx-1301 - TipRanks

May 20, 2025

May 20, 2025

Cingulate (CING) Reveals Promising Phase 3 Results for ADHD Treatment | CING Stock News - GuruFocus

May 20, 2025

May 20, 2025

Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD - GlobeNewswire

May 20, 2025

May 19, 2025

CING: Roth Capital Lowers Price Target, Maintains Buy Rating | CING Stock News - GuruFocus

May 19, 2025

May 18, 2025

CING: Roth Capital Adjusts Price Target Amidst CTx-1301 Developm - GuruFocus

May 18, 2025

May 18, 2025

Cingulate price target lowered to $11 from $12 at Roth Capital - TipRanks

May 18, 2025

May 18, 2025

CING: Roth Capital Adjusts Price Target Amidst CTx-1301 Developments | CING Stock News - GuruFocus

May 18, 2025

May 16, 2025

Cingulate Retail Buzz Rises After FDA Greenlights Summer NDA Filing For ADHD Drug - MSN

May 16, 2025

May 15, 2025

CING: First Quarter 2025 Results - Yahoo Finance

May 15, 2025

May 15, 2025

Cingulate receives FDA meeting feedback on ADHD drug By Investing.com - Investing.com Canada

May 15, 2025

May 15, 2025

Anchoring Your Portfolio: Is CING Stock a Safe Harbor? - investchronicle.com

May 15, 2025

May 15, 2025

Cingulate Retail Buzz Rises After FDA Greenlights Summer NDA Filing For ADHD Drug By Stocktwits - Investing.com India

May 15, 2025

May 15, 2025

Cingulate, Inc. Reports Increased Losses Amid R&D Expansion - TipRanks

May 15, 2025